- Home
- QFIN vs CNTA Comparison
QFIN vs CNTA Comparison
Compare QFIN & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QFIN | CNTA |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QFIN | CNTA |
|---|---|---|
| Price | $19.84 | $26.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $36.85 | ★ $37.70 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | 11-18-2025 | 11-05-2025 |
| Dividend Yield | ★ 7.67% | N/A |
| EPS Growth | ★ 40.93 | N/A |
| EPS | ★ 6.93 | N/A |
| Revenue | ★ $2,752,357,572.00 | $15,000,000.00 |
| Revenue This Year | $17.39 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.80 | ★ N/A |
| Revenue Growth | 14.06 | ★ 118.88 |
| 52 Week Low | $17.61 | $9.60 |
| 52 Week High | $48.94 | $30.58 |
Technical Indicators
Market Signals| Indicator | QFIN | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 45.51 |
| Support Level | $18.83 | $28.43 |
| Resistance Level | $19.92 | $30.02 |
| Average True Range (ATR) | 0.72 | 1.34 |
| MACD | 0.28 | -0.40 |
| Stochastic Oscillator | 86.57 | 18.64 |
Price Performance
Historical ComparisonAbout QFIN Qifu Technology Inc.
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.